K2P Channels as Key Regulators of Cardiovascular and Pulmonary Vascular Function
Pharmaceuticals · 25.03.2026 · 19 (4) · 533
DOI: 10.3390/ph19040533 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Pharmaceuticals, online erschienen am 25.03.2026. Verfasst von Hala Y Abdelnasser und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacological and Pharmaceutical Sciences, College of Pharmacy, University of Houston, Houston, TX 77204-5037, USA. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 76 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Heart Lung and Blood Institute, BLRD VA, American Heart Association.
Abstract (Originalsprache)
Two-pore domain potassium (K2P) channels are the most recently identified family of potassium channels. They are regarded as the largest group of background “leak” channels, encoded by 15 mammalian KCNK genes, and divided into six subfamilies (TWIK, TREK, TASK, TALK, THIK, and TRESK). These channels have a role in stabilizing the resting membrane potential. Their widespread presence in the heart and vasculature supports cellular homeostasis by regulating cardiac rhythm, vascular tone, and protection against ischemic stress. The TASK, TWIK, and TREK subfamilies are the most abundantly expressed K2P channel subfamilies in the cardiovascular system, and dysregulation of specific members has been strongly linked to the development of major cardiovascular diseases. Mutations in TASK-1 have been identified in patients with pulmonary arterial hypertension, providing human genetic evidence linking K2P dysfunction to pulmonary vascular disease. While alterations in other K2P channels, such as TREK-1, have been demonstrated in preclinical studies where reduced channel activity is associated with ischemia–reperfusion injury and promotes cardiac arrhythmias. Growing evidence suggests that K2P channels could serve as promising therapeutic targets, with pharmacological activation of TASK-1 and TREK-1, for instance, that might help restore vascular tone, reduce remodeling, and offer cardioprotection. Their unique leak-channel properties enable the development of highly selective treatments. This review addresses the molecular biology, physiological roles, and disease relevance of K2P channels in the cardiovascular and pulmonary systems, emphasizing their potential as targets for innovative therapies in cardiovascular diseases.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pharmacological and Pharmaceutical Sciences, College of Pharmacy, University of Houston, Houston, TX 77204-5037, USA.
- Department of Medicine, Baylor College of Medicine, Houston, TX 77030, USA.
- Pulmonary, Critical Care, and Sleep Medicine, Baylor College of Medicine, Michael E. DeBakey Veterans Affairs Medical Center, Houston, TX 77030, USA.
ORCID-Profile: Lavannya M Pandit, Bradley K McConnell
Förderung
- National Heart Lung and Blood Institute
- BLRD VA
- American Heart Association
- Grants to Enhance and Advance Research (GEAR) Award
- Robert J. Kleberg, Jr., and Helen C. Kleberg Foundation
- National Heart, Lung, and Blood Institute
- Department of Veterans Affairs
- University of Houston
Zitieren
APA
Abdelnasser, H. Y., Pi, X., Pandit, L. M., & McConnell, B. K. (2026). K2P Channels as Key Regulators of Cardiovascular and Pulmonary Vascular Function. Pharmaceuticals, 19(4), 533. https://doi.org/10.3390/ph19040533
Vancouver
Abdelnasser HY, Pi X, Pandit LM, McConnell BK. K2P Channels as Key Regulators of Cardiovascular and Pulmonary Vascular Function. Pharmaceuticals. 2026;19(4):533. doi:10.3390/ph19040533
BibTeX
@article{Abdelnasser2026,
author = {Abdelnasser, Hala Y and Pi, Xinchun and Pandit, Lavannya M and McConnell, Bradley K},
title = {K2P Channels as Key Regulators of Cardiovascular and Pulmonary Vascular Function},
journal = {Pharmaceuticals},
year = {2026},
volume = {19},
number = {4},
pages = {533},
doi = {10.3390/ph19040533}
}
EUVIMED